Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 128.90B P/E 13.80 EPS this Y -5.40% Ern Qtrly Grth -
Income 5.4B Forward P/E 10.60 EPS next Y 12.50% 50D Avg Chg -2.00%
Sales 46.03B PEG 1.73 EPS past 5Y 8.29% 200D Avg Chg 4.00%
Dividend 3.00% Price/Book 1.78 EPS next 5Y 6.40% 52W High Chg -10.00%
Recommedations 1.00 Quick Ratio 0.82 Shares Outstanding 1.25B 52W Low Chg 41.00%
Insider Own 11.37% ROA 4.54% Shares Float 1.10B Beta 0.44
Inst Own 46.80% ROE 7.27% Shares Shorted/Prior -/- Price 103.06
Gross Margin 69.12% Profit Margin 11.73% Avg. Volume 8,367 Target Price -
Oper. Margin 6.91% Earnings Date - Volume 1,720 Change -2.78%
About SANOFI

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

SANOFI News
03/28/24 Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
03/26/24 32 Countries with the Highest Rates of Diabetes
03/22/24 Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript
03/22/24 Press Release: Availability of the Q1 2024 Memorandum for modelling purposes
03/21/24 Mirador Therapeutics raises over $400 mln in early funding rounds
03/15/24 Sanofi: Information concerning the total number of voting rights and shares - February 2024
03/15/24 PE Firms Eye €7.5 Billion Buyout Financing for Sanofi Unit
03/14/24 12 Most Profitable Biotech Stocks To Invest In
03/12/24 ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
03/11/24 Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
03/07/24 UPDATE 2-Astra-Sanofi's RSV therapy 90% effective against infant hospitalizations, CDC study shows
03/05/24 13 Best Pharma Dividend Stocks To Buy in 2024
08:50 AM Pharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK
02/28/24 Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up
02/27/24 3 Cash Cow Dividend Stocks for Outsized Income & Upside
02/27/24 Denali, fresh off study setback, gets $500M lift
02/24/24 Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
02/23/24 Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
02/23/24 Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript
02/23/24 20 Fastest Growing Biotech Companies in the US